Comparing Coloplast to ConvaTec, the latter has been seeing double-digit growth in China, where Coloplast has been struggling ...

Coloplast CEO Kristian Villumsen steps down from his CEO position as of today. The Board of Directors has asked Lars Rasmussen to step in as interim CEO. As the company is entering into a new strategy ...

Coloplast's stock price has declined by 25% since April 2023, making it more attractive but still overvalued based on fundamentals and valuation multiples. Recent quarterly results show revenue growth ...

There’s something fishy about Coloplast’s latest megadeal—literally. The Danish medtech announced (PDF) plans on Friday to acquire Kerecis, which uses fish skin as the basis of its wound care products ...

Coloplast has completed the acquisition of Kerecis, announced on July 7, 2023, after receiving approval from all relevant authorities and reaching a shareholder acceptance level of 100% The terms of ...

Coloplast historically has introduced consistent innovation in its ostomy-care products, including different types of adhesives, one- and two-piece devices, and irrigation systems. Finally, we note ...

COPENHAGEN, July 7 (Reuters) - Coloplast (COLOb.CO), opens new tab has agreed to buy Iceland-based Kerecis, a biologic wound care firm that uses fish skin to develop tissue-transplant products, for up ...

Earnings Call Insights: Coloplast A/S (OTCPK:CLPBF) Q1 2025 CEO Kristian Villumsen highlighted 8% organic growth and a ...

The Coloplast Corporation is a global medical device company based on the other side of the world in Humlebaek, Denmark. But the company’s North American headquarters stand on West River Road in north ...

The average one-year price target for Coloplast A (OTCPK:CLPBY) has been revised to $29.06 / share. This is an increase of 23.79% from the prior estimate of $23.48 dated December 5, 2025. The price ...